126 related articles for article (PubMed ID: 17316431)
41. Country contextualisation of cost-effectiveness studies: lessons from Ethiopia.
Johansson KA; Tolla MT; Memirie ST; Miljeteig I; Habtemariam MK; Woldemariam AT; Verguet S; Norheim OF
BMJ Glob Health; 2019; 4(6):e001320. PubMed ID: 31908853
[TBL] [Abstract][Full Text] [Related]
42. Using value of information methods to determine the optimal sample size for effectiveness trials of alcohol interventions for HIV-infected patients in East Africa.
Li L; Uyei J; Nucifora KA; Kessler J; Stevens ER; Bryant K; Braithwaite RS
BMC Health Serv Res; 2018 Jul; 18(1):590. PubMed ID: 30064428
[TBL] [Abstract][Full Text] [Related]
43. Does directly administered antiretroviral therapy represent good value for money in sub-Saharan Africa? A cost-utility and value of information analysis.
Uthman RT; Sutton AJ; Jackson LJ; Uthman OA
PLoS One; 2018; 13(1):e0191465. PubMed ID: 29360841
[TBL] [Abstract][Full Text] [Related]
44. Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft.
Nee R; Parker AL; Little DJ; Yuan CM; Himmelfarb J; Lowe SR; Abbott KC
Clin Nephrol; 2014 Jan; 81(1):38-51. PubMed ID: 24161074
[TBL] [Abstract][Full Text] [Related]
45. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
Logman JF; Heeg BM; Herlitz J; van Hout BA
Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
[TBL] [Abstract][Full Text] [Related]
46. Cost-effectiveness of Zinc Supplementation for Prevention of Childhood Diarrhoea in Tanzania.
Saronga HP; Manji K; Liu E; Duggan CP; Menzies NA
Public Health Nutr; 2022 Mar; 25(7):1-26. PubMed ID: 35272738
[TBL] [Abstract][Full Text] [Related]
47. Breastfeeding promotion and priority setting in health.
Horton S; Sanghvi T; Phillips M; Fiedler J; Perez-Escamilla R; Lutter C; Rivera A; Segall-Correa AM
Health Policy Plan; 1996 Jun; 11(2):156-68. PubMed ID: 10158457
[TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
[TBL] [Abstract][Full Text] [Related]
49. Forecasting the Value for Money of Mobile Maternal Health Information Messages on Improving Utilization of Maternal and Child Health Services in Gauteng, South Africa: Cost-Effectiveness Analysis.
LeFevre A; Cabrera-Escobar MA; Mohan D; Eriksen J; Rogers D; Neo Parsons A; Barre I; Jo Y; Labrique A; Coleman J
JMIR Mhealth Uhealth; 2018 Jul; 6(7):e153. PubMed ID: 30054263
[TBL] [Abstract][Full Text] [Related]
50. Orthopaedic trauma care in Haiti: a cost-effectiveness analysis of an innovative surgical residency program.
Carlson LC; Slobogean GP; Pollak AN
Value Health; 2012; 15(6):887-93. PubMed ID: 22999139
[TBL] [Abstract][Full Text] [Related]
51. Cost-effectiveness in Preventive Cardiology.
Weintraub WS
Curr Treat Options Cardiovasc Med; 2004 Aug; 6(4):279-290. PubMed ID: 15212723
[TBL] [Abstract][Full Text] [Related]
52. Economic evaluations of non-communicable diseases conducted in Sub-Saharan Africa: a critical review of data sources.
Hollingworth SA; Leaupepe GA; Nonvignon J; Fenny AP; Odame EA; Ruiz F
Cost Eff Resour Alloc; 2023 Aug; 21(1):57. PubMed ID: 37641087
[TBL] [Abstract][Full Text] [Related]
53. The cost-effectiveness of hypertension management in low-income and middle-income countries: a review.
Kostova D; Spencer G; Moran AE; Cobb LK; Husain MJ; Datta BK; Matsushita K; Nugent R
BMJ Glob Health; 2020 Sep; 5(9):. PubMed ID: 32912853
[TBL] [Abstract][Full Text] [Related]
54. Primary and secondary prevention interventions for cardiovascular disease in low-income and middle-income countries: a systematic review of economic evaluations.
Aminde LN; Takah NF; Zapata-Diomedi B; Veerman JL
Cost Eff Resour Alloc; 2018; 16():22. PubMed ID: 29983644
[TBL] [Abstract][Full Text] [Related]
55. Costs and Cost-Effectiveness of Hypertension Screening and Treatment in Adults with Hypertension in Rural Nigeria in the Context of a Health Insurance Program.
Rosendaal NT; Hendriks ME; Verhagen MD; Bolarinwa OA; Sanya EO; Kolo PM; Adenusi P; Agbede K; van Eck D; Tan SS; Akande TM; Redekop W; Schultsz C; Gomez GB
PLoS One; 2016; 11(6):e0157925. PubMed ID: 27348310
[TBL] [Abstract][Full Text] [Related]
56. Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: a Markov modelling study.
Ngalesoni FN; Ruhago GM; Mori AT; Robberstad B; Norheim OF
BMC Health Serv Res; 2016 May; 16():185. PubMed ID: 27184802
[TBL] [Abstract][Full Text] [Related]
57. Cost and cost-effectiveness analysis of a bundled intervention to enhance outcomes after stroke in Nigeria: Rationale and design.
Olaniyan O; Owolabi MO; Akinyemi RO; Salako BL; Hurst S; Arulogun O; Gebregziabher M; Uvere E; Ovbiagele B
eNeurologicalSci; 2015 Jun; 1(2):38-45. PubMed ID: 26640824
[TBL] [Abstract][Full Text] [Related]
58. Provider costs for prevention and treatment of cardiovascular and related conditions in low- and middle-income countries: a systematic review.
Brouwer ED; Watkins D; Olson Z; Goett J; Nugent R; Levin C
BMC Public Health; 2015 Nov; 15():1183. PubMed ID: 26612044
[TBL] [Abstract][Full Text] [Related]
59. Cardiovascular disease research output in WHO priority areas between 2002 and 2011.
Myers L; Mendis S
J Epidemiol Glob Health; 2014 Mar; 4(1):23-8. PubMed ID: 24534332
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
